Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec 22:6:296.
doi: 10.3389/fphar.2015.00296. eCollection 2015.

Strategies for Pharmacological Organoprotection during Extracorporeal Circulation Targeting Ischemia-Reperfusion Injury

Aida Salameh  1 , Stefan Dhein  2
Affiliations
Review

Strategies for Pharmacological Organoprotection during Extracorporeal Circulation Targeting Ischemia-Reperfusion Injury

Aida Salameh et al. Front Pharmacol. .

Abstract

Surgical correction of congenital cardiac malformations or aortocoronary bypass surgery in many cases implies the use of cardiopulmonary-bypass (CPB). However, a possible negative impact of CPB on internal organs such as brain, kidney, lung and liver cannot be neglected. In general, CPB initiates a systemic inflammatory response (SIRS) which is presumably caused by contact of blood components with the surface of CPB tubing. Moreover, during CPB the heart typically undergoes a period of cold ischemia, and the other peripheral organs a global low flow hypoperfusion. As a result, a plethora of pro-inflammatory mediators and cytokines is released activating different biochemical pathways, which finally may result in the occurrence of microthrombosis, microemboli, in depletion of coagulation factors and haemorrhagic diathesis besides typical ischemia-reperfusion injuries. In our review we will focus on possible pharmacological interventions in patients to decrease negative effects of CPB and to improve post-operative outcome with regard to heart and other organs like brain, kidney, or lung.

Keywords: MMP; MPT; PARP; antioxidants; cardioplegia; cardiopulmonary bypass; organoprotection.

PubMed Disclaimer

References

    1. Alano C. C., Kauppinen T. M., Valls A. V., Swanson R. A. (2006). Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc. Natl. Acad. Sci. U.S.A. 103, 9685–9690. 10.1073/pnas.0600554103 - DOI - PMC - PubMed
    1. Alexander K. P., Anstrom K. J., Muhlbaier L. H., Grosswald R. D., Smith P. K., Jones R. H., et al. . (2000). Outcomes of cardiac surgery in patients ≥ 80 years: results from the National cardiovascular network. J. Am. Coll. Cardiol. 35, 731–738. 10.1016/S0735-1097(99)00606-3 - DOI - PubMed
    1. Andrasi T. B., Blazovics A., Szabo G., Vahl C. F., Hagl S. (2005). Poly(ADP-ribose) polymerase inhibitor PJ-34 reduces mesenteric vascular injury induced by experimental cardiopulmonary bypass with cardiac arrest. Am. J. Physiol. Heart. Circ. Physiol. 288, H2972–H2978. 10.1152/ajpheart.01039.2004 - DOI - PubMed
    1. Aneja R., Hake P. W., Burroughs T. J., Denenberg A. G., Wong H. R., Zingarelli B. (2004). Epigallocatechin, a green tea polyphenol, attenuates myocardial ischemia reperfusion injury in rats. Mol. Med. 10, 55–62. 10.2119/2004-00032.Aneja - DOI - PMC - PubMed
    1. Barta E., Pechan I., Cornak V., Luknarova O., Rendekova V., Verchovodko P. (1991). Protective effect of alpha-tocopherol and L-ascorbic acid against the ischemic-reperfusion injury in patients during open-heart surgery. Bratisl. Lek. Listy. 92, 174–183. - PubMed